Hi all,Most of the old investors understand, that MPL can be...

Hi all,

Most of the old investors understand, that MPL can be used as a stand alone drug,but the real synergies is when it is combined with other non patented anti cancer drugs.

But, when combined together as in MPL with another anti cancer drug the efficacy rate of treating the cancer is getting to the stage where we have an extreme cancer fighting combination.

Doxorubicin is generic, in that there is no patent. If PAA wishes it can trial it with not outside licensing problems. The little downside is that it is intravenous, thereby requiring a weekly dose with combination MPL tablet. The upside is that both are available in Australia and authorised by the TGA( Therapeutic Goods Administration ).

So costing are negligible with Doxuribicin costing $16 per dose.When you compare the average cost of ovarian cancer being $10k USD in their first year, as opposed to MPL and doxorubicin there is a huge cost savings to the general public. As long as it is the conducive cancer cell line , we are very much on the right track.

Ref : Cost of care for the initial management of Ovarian Cancer . Bercow et al 2017

Cancer therapy is all about optimising dose age with reduced or no side effects. That is the goal, and it’s a rare achievement. We all know people that have survived cancer but the treatment has taken a drastic toll on their health.

We are looking at a potential combination now of possibly minimal side effects in people. I say this because nausea in humans can be controlled by other inexpensive medication. This seems to be the main problem, and will be overcome.

So with this further data, we can speculate on where we will be as in for some humanity in the future, and it is looking extremely promising.

If we go to the presentation page of PAA Science Week presentation July 9 2021,you will see a cell line with Ovarian Cancer heavily impregnated with Cancer , if you follow the picture you will notice a Cancer cell line virtually free of Cancer. That is what your investment means. It’s in a clear picture and how good is that. Tremendous achievement. The numeral graph on the right shows a 10 fold reduction.

As, I said previously, in combination with these other drugs , we have something very special up our sleeve.

This is a fourth generation rapalog compound. The safety is achieved, the tumour regression is achieved, the disease progression is achieved, the adverse effects have been markedly reduced, the cost of use will be achieved ( it will be dirt cheap compared to others) , we have a target of 40 + cancers in our patent plus 30 + medical conditions that can be trialled. Eventually it will come together and thousand upon thousands of lives will be saved.

Kpax